TOMM34 Antibody (Tomm34-4.1) - BSA Free

• Reactivity: Hu
• Applications: WB, ICC/IF, IP
• Clone: Tomm34-4.1
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 1 mg/ml

TOMM34 Antibody (Tomm34-4.1) - BSA Free Summary

• Description: Novus Biologicals Mouse TOMM34 Antibody (Tomm34-4.1) - BSA Free (NBP3-11704) is a monoclonal antibody validated for use in WB, ICC/IF and IP. All Novus Biologicals antibodies are covered by our 100% guarantee.
• Immunogen: Recombinant human Tomm34
• Specificity: The mouse monoclonal antibody Tomm34-4.1 recognizes an epitope within TPR2 domain of human TOMM34 protein.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: TOMM34
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • Immunocytochemistry/ Immunofluorescence
  • Immunoprecipitation
  • Western Blot

Packaging, Storage & Formulations

• Storage: Store at 4C. Do not freeze.
• Buffer: Phosphate buffered saline (PBS), pH 7.4
• Preservative: 15mM Sodium Azide
• Concentration: 1 mg/ml
• Purity: Protein A purified

Alternate Names for TOMM34 Antibody (Tomm34-4.1) - BSA Free

• hTom34
• HTOM34P
• mitochondrial import receptor subunit TOM34
• outer mitochondrial membrane translocase (34kD)
• TOM34
• Translocase of outer membrane 34 kDa subunit
• translocase of outer mitochondrial membrane 34
• URCC3

Background

TOMM34 (Translocase of the outer mitochondrial membrane 34) is an additional component of the cellular chaperone system involved in protein folding. As the name suggests, TOMM34 was initially identified as being involved in mitochondrial protein processing. Subsequent studies have shown that TOMM34 interacts with both Hsp70 and Hsp90 and modifies their protein folding activities. In cancer, high levels of TOMM34 have been reported in bladder, colorectal and breast cancers compared to their normal tissue counterparts. In these cancers, TOMM34 promotes colorectal cancer cell growth and is a biomarker of poor outcome in early invasive breast cancer and bladder cancer. As a tumour-associated protein, TOMM34 peptide vaccination is under investigation as a therapeutic option for colorectal cancer, with significant TOMM34 cytotoxic T-lymphocyte (CTL) response observed.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: TOMM34